| Code | CSB-RA624104MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to CNTO-6785, targeting interleukin-17A (IL-17A), a pro-inflammatory cytokine central to immune responses and inflammatory pathology. IL-17A is primarily produced by Th17 cells and plays a crucial role in host defense against extracellular pathogens by promoting neutrophil recruitment and antimicrobial peptide production. Dysregulated IL-17A signaling is implicated in numerous autoimmune and inflammatory conditions, including psoriasis, rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease. Elevated IL-17A levels contribute to chronic inflammation, tissue damage, and disease progression in these disorders.
CNTO-6785 is a human monoclonal antibody that specifically neutralizes IL-17A, preventing its interaction with IL-17 receptors and subsequent inflammatory cascade activation. This biosimilar provides researchers with a valuable tool for investigating IL-17A-mediated pathways, studying Th17 cell biology, and exploring therapeutic mechanisms in inflammatory disease models. The antibody enables examination of IL-17A blockade effects on cytokine networks, immune cell function, and tissue inflammation in various experimental settings.
There are currently no reviews for this product.